Close Menu

droplet microfluidics

A federal judge upheld a $24 million jury award to Bio-Rad, while a trade court judge said Bio-Rad imported microfluidics that infringed 10x patents.

The partnership brings Mission Bio's Tapestri NGS-based single-cell sequencing platform for cancer profiling to the Chinese market.

The company plans to use the funding to further develop its Xdrop technology, which allows users to partition millions of single molecules in droplets.

The UK-based firm recently launched its Nadia system, which is compatible with the Drop-seq protocol, and plans to develop additional applications. 

As part of a new partnership, Partek Flow NGS analysis software will help researchers access single-cell RNA sequences without the need for bioinformatics expertise.

A new assay uses digital loop-mediated isothermal amplification (dLAMP) to perform phenotypic antibacterial susceptibility testing in 30 minutes.

The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments. 

With growing interest in single-cell sequencing, researchers are looking to increase the throughput while also reducing cost.

The aim of the project, called Metafluidics, is to replace cumbersome conventional approaches with a cheaper, faster, and higher-throughput microfluidics platform.

The technology uses DNAzyme-based sensors, fluorescent biomarkers, and a high-throughput particle counter to rapid identify rare targets in complex raw samples.

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.